https://www.uicc.org/membership/institut-catala-doncologia
Partner Role
As Clinical Leader, ICO is responsible for the design and conduction of iBeChange clinical studies. A pilot study (2025) and a randomized control trial (2026-2027) will be performed to assess the feasibility and efficacy of the iBeChange solution in three European institutions: Istituto Europeo di Oncologia (Milano), University of Medicine and Pharmacy Carol Davila (Bucarest), and ICO in Barcelona, with almost 2000 participants. Cancer screening program at ICO is integrated to offer iBeChange studies to participating general population. ICO’s main expertise contributions are digital health solutions and psychosocial risk assessment. ICO will also provide anonymized retrospective data from COLSCREEN study.